200
Participants
Start Date
September 5, 2025
Primary Completion Date
October 30, 2027
Study Completion Date
December 30, 2027
LBL-024 for Injection
LBL-024 , Intravenous infusion.
LBL-007 Injection
LBL-007 , intravenous infusion.
Toripalimab Injection
Toripalimab , intravenous infusion.
NOT_YET_RECRUITING
The First Hospital of Jilin University, Changchun
NOT_YET_RECRUITING
Nanjing Drum Tower Hospital, Nanjing
NOT_YET_RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute &Hospital, Tianjin
NOT_YET_RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
Yunnan Cancer Hospital, Kunming
NOT_YET_RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
NOT_YET_RECRUITING
Shanxi Bethune Hospital, Taiyuan
Nanjing Leads Biolabs Co.,Ltd
INDUSTRY